The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.
Recent Posts
- Apple sees big December quarter driven by strong iPhone 17 demand
- Amazon stock soars 10% as earnings beat estimates, company posts strong cloud growth
- Netflix announces a 10-for-1 stock split
- Amazon cloud records 20% sales growth, topping estimates
- Powell forced to stave off uprisings in markets and on his own Fed board as his term ends